Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
50 hedge funds and large institutions have $114M invested in Clearside Biomedical in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
0.06% less ownership
Funds ownership: 3.5% → 3.44% (-0.06%)
6% less funds holding
Funds holding: 53 → 50 (-3)
6% less capital invested
Capital invested by funds: $121M → $114M (-$6.89M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$827K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$523K |
| 3 |
BlackRock
New York
|
+$465K |
| 4 |
FPC
Falcon Point Capital
San Francisco,
California
|
+$360K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$2.44M |
| 2 |
Renaissance Technologies
New York
|
-$731K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$683K |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$260K |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$164K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Renaissance Technologies
New York
| – | -$731K | -5,347 | Closed |
|
|
HCM
52
Highbridge Capital Management
New York
| – | -$164K | -1,200 | Closed |
|
|
PPA
53
Parametric Portfolio Associates
Seattle,
Washington
| – | -$122K | -895 | Closed |
|
54
Citadel Advisors
Miami,
Florida
| – | -$117K | -859 | Closed |
|
55
JP Morgan Chase
New York
| – | -$32K | -231 | Closed |
|
|
PAM
56
Panagora Asset Management
Boston,
Massachusetts
| – | -$9K | -69 | Closed |
|
57
Creative Planning
Overland Park,
Kansas
| – | -$9K | -67 | Closed |
|
CLSD Hedge Fund Activity: Q3 2017 in Review
50 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2017, worth a combined $114M — down 5.7% from $121M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CLSD and 5 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 18 added.
The largest buyer was Wellington Management Group, adding an estimated $827K. The largest seller was AWM Investment Company, cutting an estimated $2.44M.
- 50 institutional investors held Clearside Biomedical (CLSD) as of Q3 2017, down from 53 in Q2 2017.
- Funds reported $114M of Clearside Biomedical stock for Q3 2017, down 5.7% quarter-over-quarter.
- 5 funds opened new Clearside Biomedical positions in Q3 2017 and 7 closed out, a net change of -2 holders.
- The largest Clearside Biomedical buyer in Q3 2017 was Wellington Management Group, an estimated $827K added.
- The largest Clearside Biomedical seller in Q3 2017 was AWM Investment Company, an estimated $2.44M sold.
Based on aggregated 13F filings for Q3 2017.